Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment

NCT00449150 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.

NCT NCT00449150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00449150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Lead sponsor
AEterna Zentaris
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2007
Completion date
December 31, 2009
Enrollment
667 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hypertrophy